This formation for mice and rats is legally marked as an FDA-indexed product under MIF 900-014. Extra-label use is prohibited.
Please see Prescribing Information for additional Important Safety Information.
Important Safety Information
WARNING: ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, and ACCIDENTAL EXPOSURE
This formulation contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.
Do not dispense this formulation.
Life-Threatening Respiratory Depression
The concentration of buprenorphine is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of this formulation. There are additive CNS depressant efects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, this formulation should only be administered by a veterinarian or laboratory staf trained in the handling of potent opioids.
We are committed to researching and developing new, innovative solutions for animal health.
Our team of experts in veterinary and human medicine have extensive experience in the commercialization of new pharmaceuticals.
Fidelis Pharmaceuticals is a proud member of AALAS and AVMA and supports the position that the appropriate use of pain management is a scientific and moral imperative. We are committed to the research and development of trusted, extended release, long-acting pain management products for laboratory animals.